1. Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

3. Program Objectives

4. Rotterdam Study

5. Burden of Atrial Fibrillation

10. Efficacy vs Safety NOAC 4-trial Meta-analysis Full Dose

12. Anticoagulation in Europe in the EORP Registry

13. Patient Comorbidities at Baseline by Type of Anticoagulant Received

14. Adequacy of INR Control

16. When Not to Use NOACs

17. Rationale for a "Registry"

19. Mean CHA2DS2-VASc and HAS-BLED Scores According to OAC Treatment

20. Distribution of OAC Treatment Among New Users With AF from 2011 to 2014

21. HAS-BLED Bleeding Risk Score

22. Anticoagulation in Europe: EORP Registry

23. Recommendations for Prevention of TE in NVAF: NOACs

24. NOAC Dose Reduction

25. Antiplatelet Treatment in the ESC Guidelines

27. NOAC Dose Reduction

28. AEGEAN Objectives

29. AEGEAN Study Design

30. Adherence (Primary Endpoint)

31. Conclusion

32. Abbreviations

33. Abbreviations (cont)

34. Abbreviations (cont)

35. Abbreviations (cont)